Poliomyelitis - Pipeline Review, H1 2017

  • ID: 4318758
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • LG Chem, Ltd.
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • MORE
Poliomyelitis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • LG Chem, Ltd.
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • MORE
  1. Introduction
  2. Poliomyelitis - Overview
  3. Poliomyelitis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Poliomyelitis - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Poliomyelitis - Companies Involved in Therapeutics Development
  14. Beijing Minhai Biotechnology Co Ltd
  15. Bharat Biotech International Ltd
  16. Biological E Ltd
  17. Biological Mimetics Inc
  18. Boryung Pharmaceutical Co Ltd
  19. Daiichi Sankyo Company Ltd
  20. GlaxoSmithKline Plc
  21. Grifols SA
  22. Johnson & Johnson
  23. Kaketsuken KK
  24. LG Chem, Ltd.
  25. Nanolek
  26. Panacea Biotec Ltd
  27. Sanofi
  28. Sanofi Pasteur SA
  29. Sentinext Therapeutics Sdn Bhd
  30. Shantha Biotechnics Pvt Ltd
  31. Taiga Biotechnologies Inc
  32. Takeda Pharmaceutical Company Ltd
  33. Poliomyelitis - Drug Profiles
  34. (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. BK-1310 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. BVN-002 - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. DTaP-IPV-HB-PRPT - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. immune globulin (human) - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. ImmunoRx - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. IPVGVI-3000 - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. JNJ-2348 - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. KD-370 - Drug Profile
  87. Product Description
  88. Mechanism Of Action
  89. R&D Progress
  90. LBVC - Drug Profile
  91. Product Description
  92. Mechanism Of Action
  93. R&D Progress
  94. LBVD - Drug Profile
  95. Product Description
  96. Mechanism Of Action
  97. R&D Progress
  98. polio (virus like particle, bivalent) vaccine - Drug Profile
  99. Product Description
  100. Mechanism Of Action
  101. R&D Progress
  102. polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
  103. Product Description
  104. Mechanism Of Action
  105. R&D Progress
  106. polio [strain Sabin] vaccine - Drug Profile
  107. Product Description
  108. Mechanism Of Action
  109. R&D Progress
  110. polio vaccine - Drug Profile
  111. Product Description
  112. Mechanism Of Action
  113. R&D Progress
  114. polio vaccine - Drug Profile
  115. Product Description
  116. Mechanism Of Action
  117. R&D Progress
  118. polio vaccine - Drug Profile
  119. Product Description
  120. Mechanism Of Action
  121. R&D Progress
  122. polio vaccine - Drug Profile
  123. Product Description
  124. Mechanism Of Action
  125. R&D Progress
  126. poliomyelitis vaccine - Drug Profile
  127. Product Description
  128. Mechanism Of Action
  129. R&D Progress
  130. poliomyelitis vaccine - Drug Profile
  131. Product Description
  132. Mechanism Of Action
  133. R&D Progress
  134. poliomyelitis vaccine - Drug Profile
  135. Product Description
  136. Mechanism Of Action
  137. R&D Progress
  138. TAK-195 - Drug Profile
  139. Product Description
  140. Mechanism Of Action
  141. R&D Progress
  142. VN-0105 - Drug Profile
  143. Product Description
  144. Mechanism Of Action
  145. R&D Progress
  146. Poliomyelitis - Dormant Projects
  147. Poliomyelitis - Discontinued Products
  148. Poliomyelitis - Product Development Milestones
  149. Featured News & Press Releases
  150. Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
  151. May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
  152. Appendix
  153. Methodology
  154. Coverage
  155. Secondary Research
  156. Primary Research
  157. Expert Panel Validation
  158. Contact Us
  159. Disclaimer
List of Tables
  1. Number of Products under Development for Poliomyelitis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1
  12. Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H1
  13. Poliomyelitis - Pipeline by Biological E Ltd, H1
  14. Poliomyelitis - Pipeline by Biological Mimetics Inc, H1
  15. Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H1
  16. Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H1
  17. Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H1
  18. Poliomyelitis - Pipeline by Grifols SA, H1
  19. Poliomyelitis - Pipeline by Johnson & Johnson, H1
  20. Poliomyelitis - Pipeline by Kaketsuken KK, H1
  21. Poliomyelitis - Pipeline by LG Chem, Ltd., H1
  22. Poliomyelitis - Pipeline by Nanolek, H1
  23. Poliomyelitis - Pipeline by Panacea Biotec Ltd, H1
  24. Poliomyelitis - Pipeline by Sanofi, H1
  25. Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1
  26. Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1
  27. Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H1
  28. Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H1
  29. Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1
  30. Poliomyelitis - Dormant Projects, H1
  31. Poliomyelitis - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Poliomyelitis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Targets, H1
  5. Number of Products by Stage and Targets, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Biological Mimetics Inc
  • Boryung Pharmaceutical Co Ltd
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson
  • Kaketsuken KK
  • LG Chem, Ltd.
  • Nanolek
  • Panacea Biotec Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Shantha Biotechnics Pvt Ltd
  • Taiga Biotechnologies Inc
  • Takeda Pharmaceutical Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll